Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients

Clinical Biochemistry

Volumn 41, Issue 10-11, 2008, Pages 779-784

  Yildiz, Ali ^a   Gur, Mustafa ^a   Demirbag, Recep ^a   Yilmaz, Remzi ^a   Akyol, Selahattin ^a   Aslan, Mehmet ^a   Erel, Ozcan ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Arylesterase; Dipper; High density lipoprotein; Hypertension; Lipid hydroperoxide; Non dipper; Paraoxonase; Total antioxidant status

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; ARYLESTERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANALYTIC METHOD; ARTICLE; ASSAY; AUTOANALYSIS; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ADULT; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BLOOD PRESSURE MONITORING, AMBULATORY; CARBOXYLIC ESTER HYDROLASES; DIASTOLE; FEMALE; HEART RATE; HUMANS; HYPERTENSION; LIPID PEROXIDES; MALE; MIDDLE AGED; PATIENT SELECTION; REFERENCE VALUES; SYSTOLE;

EID: 46549085029     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.02.010     Document Type: Article

References (35)

1. Mancia G., Ferrari A., Gregorini L., et al. Blood pressure and heart rate variabilities in normotensive and hypertensive human beings. Circ Res 53 (1983) 96-104
2. Verdecchia P., Schillaci G., and Porcellati C. Dippers versus non-dippers. J Hypertens 9 (1991) 42-48
3. Verdecchia P., Schillaci G., Guerrieri M., et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81 (1990) 528-536
4. Verdecchia P., Porcellati C., Schillaci G., et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 24 (1994) 793-801
5. Pierdomenico S.D., Lapenna D., Guglielmi M.D., et al. Arterial disease in dipper and nondipper hypertensive patients. Am J Hypertens 10 (1997) 511-518
6. Roman M.J., Pickering T.G., Schwartz J.E., Cavallini M.C., Pini R., and Devereux R.B. Is the absence of a normal nocturnal fall in blood pressure (nondipping) associated with cardiovascular target organ damage?. J Hypertens 15 (1997) 969-978
7. Canales A., and Sanchez-Muniz F.J. Paraoxanase, something more than an enzyme?. Med Clin 121 (2003) 537-548
8. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 473-480
9. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 286 (1991) 152-154
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
11. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
12. Mackness M.I., Harty D., Bhatanagar D., et al. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis 86 (1991) 193-197
13. Letellier C., Durou M.R., Jouanolle A.M., Le Gall J.Y., Poirier J.Y., and Ruelland A. Serum paraoxonase activity and paraoxonase gene polymorphism in type 2 diabetic patients with or without vascular complications. Diabetes Metab 28 (2002) 297-304
14. Uzun H., Karter Y., Aydin S., et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 18 (2004) 523-528
15. Rosenblat M., Hayek T., Hussein K., and Aviram M. Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol 24 (2004) 175-180
16. Aviram M., Rosenblat M., Billecke S., et al. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26 (1999) 892-904
17. Kabaroglu C., Mutaf I., Boydak B., et al. Association between serum paraoxonase activity and oxidative stress in acute coronary syndromes. Acta Cardiol 59 (2004) 606-611
18. Pierdomenico S.D., Costantini F., Bucci A., et al. Blunted nocturnal fall in blood pressure and oxidative stress in men and women with essential hypertension. Am J Hypertens. 12 (1999) 356-363
19. Maeda K., Yasunari K., Watanabe T., and Nakamura M. Oxidative stress by peripheral blood mononuclear cells is increased in hypertensives with an extreme-dipper pattern and/or morning surge in blood pressure. Hypertens Res 28 (2005) 755-761
20. Stergiou GS, Salgami EV. World Health Organization-International Society of Hypertension (WHO-ISH); USA Joint National Committee on Prevention, Detection, Evalutiaon, and Treatment of High Blood Pressure (JNC-7); European Soceity of Hypertension-European Society of Cardiology (ESH-ESC). New European, American and International guidelines for hypertension management: agreement and disagreement. Expert Rev Cardiovasc Ther 2 (2004) 359-368
21. Teichholz L.E., Kreulen T., Herman M.V., and Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy. Am J Cardiol 37 (1976) 7-11
22. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (1977) 613-618
23. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
24. Haagen L., and Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 30 (1992) 391-395
25. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 37 (2004) 112-119
26. Arab K., and Steghens J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 325 (2004) 158-163
27. Young I.S., and McEneny J. Lipoprotein oxidation and atherosclerosis. Biochem Soc Transact 29 (2001) 358-362
28. Casalone R., Granata P., Minelli E., et al. Cytogenic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum Genet 87 (1991) 139-143
29. Buczynski A., Wachowicz B., Kedziora-Kornatowska K., Tkaczewski W., and Kedziora J. Changes in antioxidant enzymes activities, aggregability and malonyldialdehyde concentration in blood platelets from patients with coronary heart disease. Atherosclerosis 100 (1993) 223-228
30. Russo C., Olivieri O., Girelli D., et al. Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 16 (1998) 1267-1271
31. Prabha P.S., Das U.N., Koratkar R., Sagar P.S., and Ramesh G. Free radical generation, lipid peroxidation and essential fatty acids in uncontrolled essential hypertension. Prostaglandins Leukotrienes Essential Fatty Acids 41 (1990) 27-33
32. Lacy F., O'Connor D.T., and Schmid-Schonbein G.W. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 16 (1998) 291-303
33. Witztum J.L., and Steinberg D. Role of oxidized low-density lipoprotein in atherogenesis. J Clin Invest 88 (1991) 1785-1792
34. Aviram M., and Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol 16 (2005) 393-399
35. von Kanel R., Jain S., Mills P.J., et al. Relation of nocturnal blood pressure dipping to cellular adhesion, inflammation and hemostasis. J Hypertens 22 (2004) 2087-2093